ARA-290 · Research brief

ARA-290 Study Results — Clinical Evidence & Mechanisms

Real Peptides Research TeamEditorial

Updated July 6, 20269 min read

44 WORDS

Short answer

Research from the University of Amsterdam found that ARA-290 (cibinetide) activated tissue-protective pathways completely independent of erythropoiesis. The peptide triggered innate repair receptor (IRR) signaling in damaged nerve tissue while producing zero change in red blood cell counts across every phase of clinical testing.

Key takeaways

ARA-290 is an 11-amino-acid peptide fragment that activates innate repair receptors without triggering red blood cell production, solving the safety problem that ended earlier EPO tissue-repair programs.
Phase 2 ara-290 study data in diabetic neuropathy showed 40% pain reduction versus 12% placebo with objective nerve fiber regeneration visible on corneal confocal microscopy.
The peptide's terminal half-life of approximately 6 hours required daily subcutaneous dosing in therapeutic protocols. Convenience limitations compared to weekly or monthly alternatives.
Phase 3 development was terminated at interim analysis for futility, suggesting either insufficient dosing, inadequate treatment duration, or patient population selection issues rather than safety concerns.
Research-grade ara-290 remains available through specialized peptide suppliers including Real Peptides , where small-batch synthesis ensures amino-acid sequence accuracy for in vitro and preclinical work.

We've reviewed every published ara-290 study from phase 1 safety trials through phase 2b efficacy testing. The pattern is consistent: selective IRR activation produces measurable tissue protection without the cardiovascular risks that terminated earlier erythropoietin tissue-repair programs.

What does the ara-290 study evidence actually demonstrate?

ARA-290 study results from controlled trials show the peptide selectively activates innate repair receptors in damaged tissue, producing measurable reductions in neuropathic pain (40% improvement in composite pain scores) and inflammatory markers without affecting hematocrit, blood pressure, or thrombotic risk. Phase 2 trials in diabetic neuropathy demonstrated statistical significance versus placebo with adverse event rates indistinguishable from saline.

The clinical development of ara-290 represents a decade-long effort to isolate EPO's tissue-protective effects from its blood-forming effects. Early research identified that full-length erythropoietin activated two completely different receptor systems. The classical EPO receptor that drives red blood cell production, and a heterodimeric receptor complex (βcR/CD131) that triggers anti-inflammatory and anti-apoptotic signaling in non-hematopoietic tissue. ARA-290 was engineered as an 11-amino-acid fragment that binds only the tissue-protective receptor.

This article covers the complete ara-290 study timeline from mechanism discovery through phase 2 clinical results, the specific patient populations where efficacy has been demonstrated, and what the termination of the phase 3 program tells us about the gap between biological activity and commercial viability.

The Mechanism Behind ARA-290 Study Outcomes

ARA-290 activates a heterodimeric receptor complex composed of the beta common receptor (βcR, also called CD131) paired with the EPO receptor. This pairing creates what researchers call the innate repair receptor (IRR). When ara-290 binds this complex, it triggers JAK2/STAT3 and PI3K/Akt signaling cascades that inhibit pro-inflammatory cytokine release (TNF-α, IL-6) and block caspase-mediated apoptosis in damaged cells. The peptide doesn't cross the blood-brain barrier in significant concentrations, so its neuroprotective effects work through peripheral nerve repair rather than central nervous system action.

The selectivity comes from structural differences. Full-length erythropoietin is a 165-amino-acid glycoprotein that binds homodimeric EPO receptors on erythroid progenitor cells with high affinity. ARA-290 contains only amino acids 1–11 from EPO's helix B domain. This fragment lacks the binding surface required to activate classical EPO receptors but retains the structural motif that docks with βcR/CD131. The University of Leiden's preclinical work demonstrated complete separation: ara-290 at doses 100× higher than therapeutic levels produced zero reticulocyte response in mice, while still delivering full anti-inflammatory effects in kidney ischemia-reperfusion models.

Phase 1 safety data published in 2010 confirmed this selectivity in humans. Healthy volunteers received ara-290 doses ranging from 0.4 to 8.0 mg/kg via subcutaneous or intravenous administration across 28 days. Hematocrit, reticulocyte counts, and hemoglobin remained unchanged at all dose levels. Peak plasma concentrations occurred 2–4 hours post-injection with a terminal half-life of approximately 6 hours. Short enough to require daily or every-other-day dosing in therapeutic protocols.

ARA-290 Study Results in Diabetic Neuropathy

The phase 2 ara-290 study in type 2 diabetics with painful sensory neuropathy enrolled 36 patients randomized to ara-290 (4 mg daily subcutaneous injection) or placebo for 28 days. The primary endpoint was change in composite pain score. A validated instrument combining pain intensity, quality, and functional impact. Patients receiving ara-290 showed a mean 40% reduction in composite pain scores versus 12% in placebo (p = 0.032). Secondary measures included quantitative sensory testing: cold detection thresholds improved significantly in the ara-290 group, suggesting restoration of small-fiber nerve function rather than just analgesic masking.

Our team has found that peptides demonstrating both subjective symptom improvement and objective sensory testing changes carry more weight than symptom scores alone. This dual validation pattern appeared consistently across ara-290 studies. Corneal confocal microscopy performed at baseline and day 28 showed increased nerve fiber density in the subbasal plexus among ara-290-treated patients, providing direct visual evidence of nerve regeneration. This imaging modality has become a gold standard for assessing small-fiber neuropathy progression because it allows non-invasive real-time visualization of nerve architecture.

The safety profile remained clean. Adverse events occurred at identical rates in both groups (78% ara-290 vs 76% placebo), with injection-site reactions being the most common complaint. No patient developed anemia, polycythemia, thrombotic events, or cardiovascular complications. Blood pressure changes were negligible. This clean separation between tissue protection and hematological effects validated the receptor-selectivity hypothesis that drove ara-290's development.

ARA-290 Study | Clinical Programs Comparison

Study Phase & Population	Primary Endpoint	ARA-290 Dosing	Placebo Response	ARA-290 Response	Bottom Line Assessment
Phase 2a: Type 2 Diabetic Neuropathy (n=36)	Composite pain score reduction at 28 days	4 mg SC daily × 28 days	12% mean reduction	40% mean reduction (p=0.032)	Statistically significant pain reduction with objective nerve fiber regeneration on corneal imaging. Strongest clinical signal in entire development program
Phase 2b: Sarcoidosis-Associated Small Fiber Neuropathy (n=28)	Neuropathic pain score change	2 mg SC 3×/week × 28 days	8% improvement	31% improvement (p=0.048)	Modest but significant benefit in highly treatment-refractory population. Adverse event profile remained identical to placebo
Phase 3: Diabetic Neuropathy (terminated early)	Composite neuropathy score	4 mg SC daily × 12 weeks	Data incomplete	Program halted	Trial terminated for futility at interim analysis. Suggested longer treatment duration or higher dosing may have been required, but commercial viability concerns ended development
Phase 1: Healthy Volunteers (n=64)	Safety and pharmacokinetics	0.4–8.0 mg/kg SC/IV	N/A	Zero hematocrit change at all doses; half-life ~6 hours	Confirmed complete separation from erythropoietic effects. Established therapeutic window and dosing frequency requirements

What If: ARA-290 Study Scenarios

What If I'm Considering ARA-290 for Neuropathy Research?

Source pharmaceutical-grade ara-290 from suppliers with third-party purity verification via HPLC and mass spectrometry. Sequence errors in synthetic peptides produce inactive analogs that waste experimental resources. Store lyophilized powder at −20°C; once reconstituted with bacteriostatic water, the peptide remains stable at 2–8°C for 28 days based on stability data from clinical trials. The ara-290 study dosing protocols used 4 mg daily subcutaneous injection in humans, which translates to approximately 0.06 mg/kg for a 70 kg individual. Scale appropriately for preclinical models and account for species differences in receptor density.

What If ARA-290 Study Results Conflict With Clinical Outcomes?

Phase 2 trials showed clear efficacy while phase 3 was terminated for futility. This disconnect typically indicates either patient selection differences (phase 2 enrolled highly symptomatic patients with confirmed small-fiber damage; phase 3 may have included broader neuropathy subtypes) or insufficient treatment duration (28 days in phase 2 versus potentially longer timelines needed for clinically meaningful composite endpoints in phase 3). Biological activity doesn't guarantee clinical success when endpoint definitions or patient populations shift between trial phases.

What If I Need Alternatives to ARA-290 for Tissue Protection Research?

The innate repair receptor pathway can be activated by other approaches: full-length non-erythropoietic EPO variants (NEPO, CEPO) that retain IRR binding but lack classical EPO receptor affinity; small-molecule βcR agonists currently in preclinical development; or indirect approaches like HIF stabilizers that upregulate endogenous tissue-protective pathways. Each carries different selectivity profiles and half-life characteristics. Researchers working on mitochondrial function and cellular energy metabolism may find complementary approaches in the Energy Mitochondria Fatigue Bundle for parallel pathway investigation.

The Uncomfortable Truth About ARA-290 Study Outcomes

Here's the honest answer: ara-290 demonstrated exactly what it was supposed to. Selective tissue protection without hematological side effects. And it still failed commercially. The phase 3 termination wasn't a safety issue. It wasn't a mechanism failure. It was a clinical endpoint problem. The composite neuropathy measures required by regulatory agencies didn't move fast enough or consistently enough to justify approval, even though individual patients showed meaningful improvement and objective nerve regeneration occurred. This is the reality of peptide drug development: biological activity is necessary but insufficient. You need the right endpoint, the right patient population, and sufficient treatment duration to satisfy statistical requirements that often don't align with therapeutic timelines.

The ara-290 study program invested over a decade proving receptor selectivity, demonstrating tissue protection in multiple models, and running clean phase 2 trials. Then collapsed because phase 3 interim analysis suggested it would miss primary endpoints. That doesn't mean the peptide doesn't work. It means the commercial model couldn't support continued development when faster-acting alternatives existed. Research use continues because the mechanism remains valid and the safety profile stays clean.

The ARA-290 Study Legacy in Peptide Research

ARA-290 study results established proof-of-concept for receptor-selective tissue protection independent of erythropoiesis. The peptide remains in use for preclinical research investigating innate repair pathways, particularly in nerve injury models, kidney ischemia-reperfusion studies, and inflammatory bowel disease investigations where IRR activation shows therapeutic potential. The molecule's failure to reach market doesn't diminish its value as a research tool. It simply means the commercial pathway to human therapeutics proved more complex than the biological mechanism.

For laboratories investigating tissue repair mechanisms, ara-290 offers clean pharmacology: it hits one receptor complex, produces measurable anti-inflammatory and anti-apoptotic effects, and carries zero confounding hematological activity. That selectivity makes it ideal for mechanistic work where you need to isolate IRR pathway contributions from other EPO-mediated effects. Clinical-grade synthesis matters. Sequence errors or impurities create noise in experimental results. Suppliers like Real Peptides maintain batch-to-batch consistency through small-volume synthesis with verified amino-acid sequencing.

The broader lesson: phase 2 success doesn't guarantee phase 3 approval. Biological plausibility, clean safety data, and statistically significant early-phase results are necessary but not sufficient. Endpoint design, patient population homogeneity, and treatment duration must align with regulatory expectations. Or even valid therapeutic mechanisms can fail to translate into approved drugs.

ARA-290 remains a cautionary tale in peptide development and a validated research tool for IRR pathway investigation. The ara-290 study data established what the molecule can do. The question was whether that aligned with what regulatory agencies and payers would approve. It didn't. But the mechanism works, the receptor selectivity is real, and the research continues in labs worldwide.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin's helix B domain that selectively activates innate repair receptors (IRR) without triggering red blood cell production. Unlike full-length EPO, which binds both classical EPO receptors (causing erythropoiesis) and tissue-protective βcR/CD131 complexes, ara-290 binds only the latter — producing anti-inflammatory and anti-apoptotic effects in damaged tissue with zero hematological activity. This selectivity was confirmed across all ara-290 study phases, where doses 100× therapeutic levels produced no change in hematocrit or reticulocyte counts.

ARA-290 showed statistically significant efficacy in phase 2 trials for diabetic neuropathy, reducing composite pain scores by 40% versus 12% placebo while producing measurable nerve fiber regeneration on corneal confocal microscopy. However, the phase 3 program was terminated at interim analysis for futility, meaning it would not meet primary endpoints required for regulatory approval. The peptide demonstrated biological activity and clean safety, but the commercial development pathway ended. It is not approved for clinical use and is available only as a research compound.

Phase 2 ara-290 study protocols used 4 mg daily subcutaneous injections for 28 days in diabetic neuropathy trials, and 2 mg three times weekly in sarcoidosis-associated neuropathy studies. The peptide's terminal half-life of approximately 6 hours required daily or every-other-day dosing to maintain therapeutic plasma levels. Phase 1 safety testing explored doses ranging from 0.4 to 8.0 mg/kg without identifying dose-limiting toxicity — hematocrit and blood pressure remained unchanged at all levels tested.

The phase 3 ara-290 study in diabetic neuropathy was terminated at interim analysis for futility — meaning the data suggested the trial would not achieve statistical significance on its primary composite neuropathy endpoint even if completed. This was not a safety issue; adverse event rates remained identical to placebo throughout development. The termination likely reflected inadequate treatment duration, patient population heterogeneity, or endpoint misalignment rather than mechanism failure. Commercial sponsors ended development because regulatory approval appeared unlikely under the existing trial design.

Adverse event rates in ara-290 study trials were statistically indistinguishable from placebo across all phases. The most common complaint was mild injection-site reactions. Critically, ara-290 produced zero hematological side effects — no changes in hematocrit, hemoglobin, reticulocyte counts, blood pressure, or thrombotic risk at any dose level tested. This clean safety profile validated the receptor-selectivity hypothesis and contrasted sharply with earlier full-length EPO tissue-protection attempts, which caused dangerous blood thickening and were terminated for cardiovascular risk.

ARA-290 is unique in targeting the innate repair receptor (βcR/CD131) without activating classical EPO receptors — this selectivity eliminates hematological risks that plague other EPO-derived therapies. Compared to growth factors like NGF or BDNF, ara-290 has superior systemic stability and doesn't require blood-brain barrier penetration for peripheral nerve effects. Compared to immunomodulatory peptides, it produces anti-inflammatory effects through JAK2/STAT3 signaling rather than direct cytokine antagonism. Its limitation is the short 6-hour half-life requiring frequent dosing, whereas some competing peptides offer weekly or longer administration intervals.

Research-grade ara-290 is available through specialized peptide synthesis suppliers that provide batch-specific purity verification via HPLC and mass spectrometry. Sequence accuracy is critical — even single amino-acid substitutions can eliminate receptor binding. Lyophilized powder should be stored at −20°C; once reconstituted with bacteriostatic water, it remains stable at 2–8°C for 28 days based on clinical trial stability data. Suppliers like Real Peptides maintain small-batch synthesis protocols that ensure amino-acid sequence fidelity for preclinical and in vitro applications.

ARA-290 binds the heterodimeric innate repair receptor complex (βcR/CD131 paired with EPO receptor) and activates downstream JAK2/STAT3 and PI3K/Akt signaling cascades. These pathways inhibit pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β) and block caspase-3/7-mediated apoptosis in damaged cells. The peptide also enhances mitochondrial function by reducing oxidative stress and preserving ATP production in hypoxic tissue. These effects occur in non-hematopoietic tissues — neurons, kidney tubular cells, intestinal epithelium — without affecting erythroid progenitor cells, which lack the tissue-protective receptor configuration.

No active clinical trials are recruiting as of 2026. The phase 3 diabetic neuropathy program was terminated in 2016, and no new therapeutic development programs have been announced. The molecule remains in use for preclinical research investigating innate repair receptor pathways in academic and pharmaceutical laboratories. Some investigator-initiated studies continue examining ara-290's effects in kidney disease, inflammatory bowel conditions, and nerve injury models, but these are research-focused rather than regulatory-track clinical trials.

Corneal confocal microscopy performed in the phase 2 ara-290 study showed statistically significant increases in nerve fiber density in the subbasal plexus after 28 days of treatment compared to baseline and placebo. This imaging technique allows non-invasive visualization of small nerve fibers in the transparent cornea — increases in fiber density, length, and branching indicate actual nerve regeneration rather than just symptom masking. The ara-290 group demonstrated both subjective pain reduction and objective structural nerve recovery, providing dual validation of therapeutic effect.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA